Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of British Columbia
$27,000.00
Survival outcomes of imipridone therapy for diffuse midline glioma treatment
FY 2025-26
Summary
Diffuse midline gliomas (DMG) are rare but very fast-growing brain tumours that mostly affect children and young adults. Sadly, fewer than 10% of people with this disease live longer than two years after they are diagnosed, and right now there is no cure. Treatment options have stayed the same for more than 40 years. Radiation can improve how patients feel and what they are able to do for a short time. Chemotherapy has not been shown to help patients live longer or make them feel better. A new drug called ONC201, that is a part of a group of similar medicines, has recently gained attention because early reports suggest it may help some patients live longer. However, ONC201 is not available in Canada or many other countries around the world, and joining clinical trials for this drug is very hard. Because there are so few treatment options, many families try to get ONC201 on their own. This can cause a lot of emotional stress, travel problems, and high out-of-pocket costs. Our study will gather real-world information from patients around the world who have taken ONC201 and compare them to similar patients who did not receive the drug. By doing this we hope to learn how well ONC201 works for treating DMG, and if certain groups of patients may improve more than others after taking the drug. The results of this research will help families and health-care providers make better decisions about treatment with more information. It will also support efforts to improve access to promising drugs like ONC201 for patients in Canada.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572961
Name
Puetz Lydia R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Survival outcomes of imipridone therapy for diffuse midline glioma treatment
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer Treatment; Clinical Research; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma; Imipridones; Matched Control Cohort; Onc201; Pediatric Brain Cancer; Real World Data; Survival Outcomes
Abstract
Diffuse midline gliomas (DMG) are rare but very fast-growing brain tumours that mostly affect children and young adults. Sadly, fewer than 10% of people with this disease live longer than two years after they are diagnosed, and right now there is no cure. Treatment options have stayed the same for more than 40 years. Radiation can improve how patients feel and what they are able to do for a short time. Chemotherapy has not been shown to help patients live longer or make them feel better. A new drug called ONC201, that is a part of a group of similar medicines, has recently gained attention because early reports suggest it may help some patients live longer. However, ONC201 is not available in Canada or many other countries around the world, and joining clinical trials for this drug is very hard. Because there are so few treatment options, many families try to get ONC201 on their own. This can cause a lot of emotional stress, travel problems, and high out-of-pocket costs. Our study will gather real-world information from patients around the world who have taken ONC201 and compare them to similar patients who did not receive the drug. By doing this we hope to learn how well ONC201 works for treating DMG, and if certain groups of patients may improve more than others after taking the drug. The results of this research will help families and health-care providers make better decisions about treatment with more information. It will also support efforts to improve access to promising drugs like ONC201 for patients in Canada.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Puetz, Lydia R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~